BiotechTube

Trabectedin + Dexamethasone

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liposarcoma,Myxoid

Conditions

Liposarcoma,Myxoid

Trial Timeline

Apr 1, 2007 → Jan 1, 2010

NCT ID
NCT00579501

About Trabectedin + Dexamethasone

Trabectedin + Dexamethasone is a phase 2 stage product being developed by Johnson & Johnson for Liposarcoma,Myxoid. The current trial status is completed. This product is registered under clinical trial identifier NCT00579501. Target conditions include Liposarcoma,Myxoid.

What happened to similar drugs?

0 of 1 similar drugs in Liposarcoma,Myxoid were approved

Approved (0) Terminated (0) Active (1)
🔄Abemaciclib + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00579501Phase 2Completed
NCT00050414Phase 2Completed
NCT00050440Phase 2Completed

Competing Products

12 competing products in Liposarcoma,Myxoid

See all competitors
ProductCompanyStageHype Score
Abemaciclib + PlaceboEli LillyPhase 3
44
efatutazoneDaiichi SankyoPhase 2
35
Eribulin MesylateEisaiPhase 1
33
Yondelis + Yondelis + Dexamethasone + DexamethasoneJohnson & JohnsonPhase 2
35
HDM201 + LEE011NovartisPhase 1
29
pazopanibNovartisPhase 2
35
PF-07220060 + MidazolamPfizerPhase 2
39
Sunitinib Malate (SU011248)PfizerPhase 2
35
CabazitaxelSanofiPhase 2
35
INCMGA00012 + PalbociclibIncytePhase 2
36
Selinexor + PlaceboKaryopharm TherapeuticsPhase 2/3
28
Selinexor + IxazomibKaryopharm TherapeuticsPhase 1
11